News items 2015

  • Reassessment of ATC group A, Alimentary tract and metabolism

    | 18 December 2006 |

    At the beginning of 2007, the Danish Medicines Agency is going to begin the reassessment of ATC group A, alimentary tract and metabolism, starting with.

  • Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

    | 18 December 2006 |

    At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.

  • Reassessment of reimbursement status

    | 18 December 2006 |

    This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.

  • Reassessment of reimbursement status of ATC-groups C01, C04 and C05

    | 18 December 2006 |

    At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.

  • Reassessment of ATC-groups C01, C04 and C05

    | 18 December 2006 |

    At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.

  • Reassessment of reimbursement status of the remaining subgroups of ATC group C

    | 18 December 2006 |

    The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right.

  • Reassessment of reimbursement status for medicinal products for hypertension

    | 18 December 2006 |

    In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.

  • Reimbursement status of medicinal products aginst hypertension

    | 18 December 2006 |

    On 6 March 2006, the Danish Medicines Agency wrote a letter to a number of scientific societies to make them clarify certain aspects of the treatment of hypertension in Denmark.

  • Letter to scientific societies on treatment of hypertension

    | 24 April 2006 |

    As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.

  • Reassessment of subgroups in ATC group C

    | 24 April 2006 |

    The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.

  • Danish Medicines Agency to send safety information directly to healthcare professionals

    When side effects or the like is discovered for medicines, the medicine’s product information sometimes needs to be changed to the point that healthcare professionals must be informed directly. Up to

  • New report: Evaluation of the relationship reform

    The framework for collaboration between healthcare professionals and companies has just been evaluated. The evaluation concluded that the rules and administration work well, but compliance with the rules lags behind. There is a need for more information to healthcare professionals about the rules.

  • New EU rules on falsified medicines

    When new EU rules enter into force on 9 February 2019, it will be harder for falsified medicines to reach patients in the EU. The new rules, which introduce new safety features on the packaging of medicines and other measures, are to prevent falsified medicines from entering the legal supply chain of medicines – for example in pharmacies and hospitals.

  • The Danish Medicines Agency has a new and improved website

    More targeted news categories, new user-specific entry points and more user-friendly features are some of the new elements of the latest update of the Danish Medicines Agency’s website accessible from today.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.